The Orient‐31 study reported an advantage of a chemotherapy‐containing four‐drug therapy (sintilimab plus bevacizumab biosimilar plus cisplatin and pemetrexed) over chemotherapy alone in patients with EGFR‐mutated NSCLC after TKI failure.23 This evidence concerns the gene EGFR and non-small cell lung carcinoma.